Sunday, June 22, 2025

Latest

Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research

Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms. The two will work together on an exclusive research basis to advance the study of psilocybin in the treatment of cancer, as well as the discovery of novel uses of undisclosed psychedelic compounds.

Under the collaboration, Revive will have the exclusive right to advance research on the use psilocybin in the treatment of cancer. The partnership will also enable the company to utilize Pharmather’s AI technology, known as panaceAI, to screen, identify, and evaluation psychedelic compounds while focused on pre-specified targets for use with the firms proprietary oral thin film drug delivery technology.

The research jointly conducted will see a focus placed on utilizing Revive’s oral thin film drug delivery technology, which has been optimized for the use of psilocybin and other psychedelics. The company indicated that it will be looking to advance the development of psilocybin in the treatment of numerous types of cancer, including liver carcinoma, melanoma, kidney neoplasms, acute myeloid leukemia, and breast neoplasms.

“We recently achieved an important milestone in expanding our patent portfolio with the potential of psilocybin to treat certain cancer indications. Our research collaboration with Revive validates our business model in discovering novel uses of psychedelics with panaceAI™ and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics.”

Fabio Chianelli, CEO of PharmaTher Inc.

Revive Therapeutics last traded at $0.22 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Pharmather Appoints Dr Alberto J Espay As Scientific Advisor

Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific...

Wednesday, November 11, 2020, 08:29:13 AM

Revive Therapeutics Selects Novotech As APAC Contract Research Organization

Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a...

Wednesday, April 8, 2020, 09:37:45 AM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM

Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury

Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a...

Friday, March 19, 2021, 07:47:09 AM

PharmaTher Secures Japanese Patent For Ketabet

PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its...

Tuesday, November 30, 2021, 09:52:00 AM